About us

COMPANY PROFILE

In Greece, all the Active Pharmaceutical Ingredients (APIs) used in the production of biosimilar medicines are imported. Their domestic biotechnological production in purified form, as well as the manufacturing of innovative biomedical engineering products, could positively contribute to growth over time of the National Economy.

This reasoning was born after a lengthy search of the relevant international scientific literature and was the driving force behind the creation of BReMeL. It’ s about a biotech company under construction, initially in the form of a laboratory unit with the prospect of being transformed into an industrial-scale unit of bioproducts. State of the art cell and tissue engineering techniques will be applied for products development.

BReMeL's design includes the function of three Departments, priority being given to activating Department A:

Α. Department of Production (commercial)

Β. Department of Research - Diagnosis (scientific)

C. Department of Education - Information (educational)

Α. Department of Production:

Α1. Section of APIs production

Α2. Section of Regenerative Medicine products

Β. Department of Research and Diagnosis:

Β1. Research section

Β2. Diagnostic section

C.Department of Education and Information:

C1. The New Scientists training section

C2. Audience information section

The subject matter of all Departments will have as a reference application one or several techniques from three fields of modern biology:

1) Cell cultures from Cellular Biology

2) Recombinant DNA from Molecular Biology and Genetic Engineering

3) Induced pluripotent stem cells (iPSCs) from Developmental Biology

Specifically, BReMeL targets:

Α1. Section of APIs production

(a) the production of recombinant insulin in the purified form in accordance with the specifications of the corresponding monograph of the European Pharmacopoeia VIII.

(b) the isolation of purified recombinant hepatitis-B antigen (r-HBsAg) to produce the corresponding vaccine.

(c) the production of additional peptide-containing active substances and nonpeptide-like antibiotics (penicillin, cephalosporins, etc), as well.

Α2. Section of Regenerative Medicine products

a) the production of cellular grafts: on stroke, skeletal myoblast graft for treatment of myocardial infarction

b) the production of tissue grafts: skin substitute, biosynthetic cartilage implants, bone/ocular/ vascular implants

c) the creation of a bank for artificial skin grafts with antimicrobial properties.

Β1. Research section

a) Generation of a specialized cell line for easier insulin production.

(b) Induction of mesenchymal stem cells (MSCs) from adipose tissue/bone marrow/cord blood/ umbilical tissue to form cell types with specific phenotypic characteristics (the study of neurodegenerative disorders).

c) Creation of a bank for cell lines cryopreservation.   

d) Search emphasis on the current HOT ISSUE of the therapeutic use of CAR T-cells on hematopoietic malignancies and solid tumors.

Β2. Diagnostic section

a) Personalized Oncology: monitoring of therapeutic protocols with anti-neoplastic drugs in the 3-D cell culture environment.

b) Clinical Genetics: Detection of gene mutations and polymorphisms.

C1. The New Scientists training section

Theoretical seminars and practical training of young scientists in modern techniques of Cell Cultures / Molecular Biology and their biotechnological applications -- Publication of a relevant scientific text-book.

C2. Audience information section                    

Lectures, presentations, etc. to inform the public on the current issues of Medical Biotechnology and Bioethics -- Issue of a bimonthly newsletter.

Curriculum Vitae:                     

Name:           Dimitrios 

Surname:      Bouzianas

Affiliation:    BReMeL

Address:        Thermaikou 4, PC 555-34, Thessaloniki-Macedonia,  Greece

Tel/Mob:      +30 2310 934094 / +30 698 98 24 515 

E-mail:          dimbou55@gmail.com

Skype:           dimbou55@gmail.com

URL:              www.bremel.gr

LinkedIn:       linkedin.com/in/dimitrios-bouzianas-ceo-at-bremel-32797015b

QUALIFICATIONS:

• Graduate in Pharmacy 1978 - Aristotle University of Thessaloniki (AUTH)
• Postgraduate Teaching Qualification 1989 - SELETE, Thessaloniki
• Graduate in Biology 1993 - AUTH
• PhD in Medicine 2000 (with honors) - AUTH 

RESEARCH INTERESTS:

• Specialist in Cell Culture techniques: My main research interest focuses on the field of cell culture techniques. As a visiting scientist, I studied them at the Paterson Institute of Christie Hospital, Manchester-England and maintained long-term cooperation.
• Anthrax bioterrorism
• Therapeutic use of omega-3 fatty acids in the metabolic syndrome.
• Development of a new therapeutic method with anti-CD19 CAR-T cells against B-cell hematological malignancies.

SCIENTIFIC/PROFESSIONAL EXPERIENCE and ACHIEVEMENTS:

• Twenty years' professional experience as a Pharmacist Officer in the Greek Army, 1978-1998 (currently, retired Colonel).
• Attendance at the 24^th International Congress of Military Medicine-Pharmacy in Athens-GREECE, 1982.
• Attendance (as co-author of a paper) at the 3^rd International Congress of Pharmaceutical Technology, Paris-FRANCE, 1983.
• Member of the Hellenic Biochemical and Biophysical Society, 1996.
• Former Research Associate in Laboratory of Histology-Embryology, Faculty of Medicine, Aristotle University of Thessaloniki, 1996-1998.
• Visiting scientist to study cell culture techniques at the Paterson Institute, Christie Hospital, Manchester, England, 1995 and 2000.
• Organization of the Cell Culture Department in Laboratory of Histology-Embryology, Faculty of Medicine, AUTH, 1996-1997, where I completed my Ph.D. in 1999, working on long-term bone marrow cultures.
• Lecture to the staff of the 1^st University Internal Medicine Clinic of the AHEPA hospital in Thessaloniki, titled: "Long-term bone marrow cultures and their clinical applications", May 1996.
• As an invited lecturer, lecture to the staff of the Hematological Clinic of the University Hospital, Heraklion, island Crete-GREECE, titled: "Study of the biological behavior of hematopoietic stem cells under culture conditions", Dec. 2000.
• Holder of a national letters Patent for a new way of assessing the potential of human bone marrow primitive hematopoietic stem cells, with number: 1003638 / 02 Aug. 2001 / Greek Industrial Property Organization. Due to the innovative topic, a search was exclusively performed by the European Patent Office at the Hague in Holland - Application number: GO4247, GR2000100232, August 2001, (published in the journal Methods in Cell Science, 2003; 25 (3-4):201-210).
• Eight years' teaching experience as an Assistant Professor in the Departments of Medical Laboratories and Animal Production: Teaching of Clinical Immunology (laboratory lesson), Veterinary Pharmacology and Seminars to the last year undergraduate students, 2000-2008.
• Two years' teaching experience in Public Institutes of Vocational Education, 2000-2002.
• Authorship of part of Clinical Pharmacology for the students in the Dept. of Medical Laboratories, 2002-2005.
• Authorship of a textbook of Pharmacology, entitled "Lessons of Veterinary Pharmacology", publisher: “Synchroni Pedia”, Thessaloniki 2006. It is distributed to students in the Department of Animal Production at the University-level Technological Educational Institutes of Greece, as well as in the Department of Animal Production at the Athens Agricultural University, 2006. link: http://www.gbip.gr/book/153725
• Invited speaker at the 2^nd World Conference on Magic Bullets, organized on the occasion of the 100th Anniversary of the Nobel Prize awarded to Paul Ehrlich, October 2008, Nurnberg – Germany (oral presentation: “Current medical countermeasures – vaccines, antibodies, antibiotics - to protect humans from the anthrax bioterrorism”).
• Call to give a lecture at the 1^st BIT's World Congress of Vaccine, Dec. 2008, Guangzhou - China.
• Inclusion in the 26th American edition of 2009 of "Who's Who in the World".
• Participation in 5 Hellenic Medical Congresses with 8 papers concerning bone marrow cultures (normal and MDS patients) and 4 Congresses organized by the Hellenic Medical Corps, 1986-2000.
• Participation in 3 Hellenic Seminars and 5 Meetings on various themes e.g. HLA histocompatibility, Rheumatoid arthritis, MDS, Leukemias etc, 1986-2000.
• Invitation for the Board Membership of the journal "The Open Vaccine Journal" (October 2007).
• Invitation for the Editorial Advisory Board Membership of the journal "Inflammation and Allergy - Drug Targets" (July 2008).
• The reviewer of papers considered for publication in the journals "Anti-Infective Agents in Medicinal Chemistry", “World Journal of Gastroenterology”, “World Journal of Hepatology” (2008, 2015).
• Invitation for oral or poster presentation at numerous world congresses from 2008 until today: subject of presentations concerning anthrax bioterrorism, omega-3-fatty acids, stem cell biology and CAR-T cells therapy.
• Invitation for article and book chapters contribution to numerous journals from 2007 until today: "The Open Vaccine Journal" - "The Open Tissue Engineering and Regenerative Medicine Journal" - "Critical Care" - "Laboratory Investigation" - "The Open Biomedical Engineering Journal" - "Virology Journal" etc.
• Work contracted with AHEPA University Hospital, Laboratory of Molecular Endocrinology, for solving a research topic related to Molecular and Cellular Biology, Aug. 2009.
• Collaboration with Prof. Nohad Gresh of Universite Paris Descartes, Faculty de Medicine de Paris - France for inactivation of anthrax toxin, 2008-2010.
• Authorship of a monograph, in collaboration with the Neurology clinic of the University Hospital of “Papanikolaou”-Thessaloniki, entitled: "Stem cells in Alzheimer's Disease" (No. of notarial deed filing: 398/7-12-2011).
• Published papers: In "Greek Medicine" and in 5 peer-reviewed international journals, in http://www.ncbi.nlm.nih.gov/pubmed/?term=Bouzianas+D
• http://pubs.acs.org/doi/citedby/10.1021/jm901024b this work (without second author) was chosen by the largest scientific society in the world, the American Chemical Society (ACS) and among the papers published in its 39 peer-reviewed journals, for the weekly PressPac of June 23, 2010, which provides information to Public. Title: “New medical weapons to protect against anthrax attacks”, please click on the following 2 links: http://www.acs.org/content/acs/en/pressroom/presspacs/2010/acs-presspac-june-232010/new-medical-weapons-to-protect-against-anthrax-attacks.html and http://www.acs.org/content/acs/en/pressroom/presspacs/2010/acs-presspac-june-232010.html  
• Impact of the above paper on the USA public awareness: 
• α) Why is Dimitrios G. Bouzianas an expert in Anthrax?   http://www.expertscape.com/ar/anthrax/a/Bouzianas%2C+Dimitrios+G
• β) Study says the U.S. advancing technology to fight bioterror - by BioPrepWatch (BPW), an internet-based newswire in Chicago:  http://bioprepwatch.com/news/study-says-u-s-advancing-technology-to-fight bioterror/213523/ and http://bioprepwatch.com/about-us/
• γ) New Medical Weapons to Protect Against Anthrax Attacks: http://www.infectioncontroltoday.com/news/2010/06/new-medical-weapons-to-protect-against-anthrax-at.asp
• δ) Ready for an Anthrax Attack: New Generation of Vaccines and Antibiotics Under Development: http://beforeitsnews.com/healthcare/2010/06/ready-for-an-anthrax-attack-new-generation-of-vaccines-and-antibiotics-under-development-85131.html
• Citations by other authors: 101 citations in total -- Link: http://www.scopus.com/authid/detail.url?authorId=8363196400
  
• Participation in the 1^st “Venture Garden” Seminars regarding Business Management of Start-Up Companies, organized by the ACT American College of Thessaloniki, Mar – May 2015.
• Guest speaker, as Managing Director of the Biotechnology Company BReMeL, at the University of Thessaly Workshop entitled "Recent Advances in Cell Culture and Tissue Engineering" - Lecture Title : "Just like in the world of cinema, cell culture is moving from 2D to 3D manipulation: Focus on clinical grade bio-scaffold engineered mesenchymal stem cells for tissue repair", 08 Mar 2016.
• National Strategic Reference Frame (NSRF) 2007-2013: Selection of submitted investment program for funding with the maximum amount of ~ €300.000; characterized as "extremely dynamic" project and its innovation was graded with excellent (20/20).
• Pending submission of a European patent issue to secure an innovative method (DoLeBI) of anti-CD19 CAR-T cells against B-acute lymphoblastic leukemia, May-Jun 2019.
• Recently, the paper titled "Potential treatment of human non-alcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids" indexed in the citation database “Web of Science Core Collection”... more